Sid Sijbrandij

Just an eye.

Maybe not going to be friends.

Yeah, we assume that it's not gone.

And the only reason it'd be gone, we know that the surgery didn't cure it, that they left so-called positive margins.

So they left cancer.

The only thing that was remarkable when we...

the cancer we've removed, we were able to flesh free some of it, which is amazing for people with cancer.

It's way better to flesh free stuff because it allows you to do many, many more

diagnosis on it later than if you do the standard, which is FFPE, which preserves it, but it precludes you from doing a ton of tests.

So if you want to have an active role in your treatment, you've got to convince the hospital to flesh-free some of it so that you preserve optionality to run these diagnostics later.

And what we saw was that the T-cell infiltration went up a lot.

It went up from 20% to 90%.

So the place was buzzing with T cells, which is a good thing.

And we think that is a combination of the two checkpoint inhibitors that I'm taking that kind of unleash your immune system and one experimental treatment that is an oncolytic virus, so like a modified common cold virus

that drops the TGF beta.

And the TGF beta is something the cancer uses to hide from the immune system.

And it kind of tears away that invisibility cloak.

So that's good news.

We don't super think that that's curative.

But I'm gearing up in two weeks to take an mRNA vaccine.